Poolbeg Pharma (POLB) Competitors GBX 3.10 +0.10 (+3.33%) As of 11:52 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock POLB vs. REDX, ETX, SBTX, COS, C4XD, FUM, DDDD, TRX, SAR, and ARECShould you be buying Poolbeg Pharma stock or one of its competitors? The main competitors of Poolbeg Pharma include Redx Pharma (REDX), e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), Futura Medical (FUM), 4D pharma (DDDD), Tissue Regenix Group (TRX), Sareum (SAR), and Arecor Therapeutics (AREC). These companies are all part of the "biotechnology" industry. Poolbeg Pharma vs. Its Competitors Redx Pharma e-therapeutics SkinBioTherapeutics Collagen Solutions plc (COS.L) C4X Discovery Futura Medical 4D pharma Tissue Regenix Group Sareum Arecor Therapeutics Redx Pharma (LON:REDX) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings. Which has more volatility and risk, REDX or POLB? Redx Pharma has a beta of -0.53, indicating that its share price is 153% less volatile than the S&P 500. Comparatively, Poolbeg Pharma has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Which has stronger valuation and earnings, REDX or POLB? Redx Pharma has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRedx Pharma£4.20M0.00-£33.16M-£0.10N/APoolbeg PharmaN/AN/A-£4.50B-£851.820.00 Does the media prefer REDX or POLB? In the previous week, Redx Pharma's average media sentiment score of 0.00 equaled Poolbeg Pharma'saverage media sentiment score. Company Overall Sentiment Redx Pharma Neutral Poolbeg Pharma Neutral Is REDX or POLB more profitable? Poolbeg Pharma's return on equity of -32.56% beat Redx Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Redx PharmaN/A -180.80% -43.95% Poolbeg Pharma N/A -32.56%-21.33% Do institutionals & insiders believe in REDX or POLB? 72.7% of Redx Pharma shares are owned by institutional investors. Comparatively, 1.2% of Poolbeg Pharma shares are owned by institutional investors. 18.4% of Redx Pharma shares are owned by company insiders. Comparatively, 24.7% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryPoolbeg Pharma beats Redx Pharma on 5 of the 9 factors compared between the two stocks. Get Poolbeg Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart POLB vs. The Competition Export to ExcelMetricPoolbeg PharmaBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£15.93M£139.27M£5.74B£3.20BDividend YieldN/A3.74%4.44%5.04%P/E Ratio0.003.9030.37165.53Price / SalesN/A4,097.98453.49310,183.61Price / Cash2.1113.1937.0327.94Price / Book0.0048.418.946.00Net Income-£4.50B-£90.99M£3.26B£5.89B7 Day Performance0.98%2.05%-0.19%53.73%1 Month Performance0.65%5.76%3.83%49.09%1 Year Performance-75.46%185.09%28.77%106.09% Poolbeg Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)POLBPoolbeg PharmaN/AGBX 3.10+3.3%N/A-76.9%£15.93MN/A0.0012REDXRedx PharmaN/AN/AN/AN/A£58.35M£4.20M-150.00101Gap UpHigh Trading VolumeETXe-therapeuticsN/AN/AN/AN/A£52.59M£295K-450.0035High Trading VolumeSBTXSkinBioTherapeuticsN/AGBX 14.32+2.3%N/A+22.4%£32.70M£1.56M-8.8011COSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeFUMFutura MedicalN/AGBX 9.70-1.6%N/A-74.4%£30.23M£8.68M-8.0012Gap DownDDDD4D pharmaN/AN/AN/AN/A£30.05M£718K-1.08106TRXTissue Regenix GroupN/AGBX 30+3.4%N/A-50.0%£27.05M£31.98M-30.97120SARSareumN/AGBX 19.90+3.4%N/A-12.1%£24.86MN/A-4.713,211News CoverageGap UpARECArecor TherapeuticsN/AGBX 63.11-0.6%N/A-26.9%£23.83M£6.04M-2.2310 Related Companies and Tools Related Companies REDX Competitors ETX Competitors SBTX Competitors COS Competitors C4XD Competitors FUM Competitors DDDD Competitors TRX Competitors SAR Competitors AREC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:POLB) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poolbeg Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Poolbeg Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access